Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 320

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 320
---
Commercialize the Lumee Oxygen product and prepare for and execute commercial launch of the Lumee CGM product. • Purchase price paid by the Company to Profusa is fair to the Company from a financial point of view.Based on Marshall & Stevens’ fairness opinion, NorthView Management’s analysis and legal due diligence, the NorthView Board determined that the value of the consideration to be deliver by the Company to Profusa shareholders is fair to the Company from a financial point of view. Marshall & Stevens specifically provided the opinion that the value of the consideration to be provided by the Company to Profusa shareholders in the Merger, as provided in the Merger Agreement, is fair to the Company from a financial point of view. 161 The NorthView Board also considered a variety of uncertainties, risks and other potentially negative factors relating to the Merger including, but not limited to, the following: redemptions, complexities related to the stockholder vote, litigation and threats of litigation and broader macroeconomic risks, including Profusa’s status as an early stage company without an operating history, the competitive landscape, the uncertainties of FDA approval and the execution risk that could create difficulties for Profusa in effectively managing its commercialization and distribution of its products and, subsequently, managing its growth and expanding its operations. Specifically, the NorthView Board considered the following issues and risks: • Risk that the benefits described above may not be achieved.The risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe. • Risk of the liquidation of NorthView.The risks and costs to NorthView if the Merger is not completed, including the risk of diverting management’s focus and resources from other business combination opportunities, which could result in NorthView being unable to effect a business combination in the requisite time frame and force NorthView to liquidate. • Exclusivity.The fact that the Merger Agreement includes an exclusivity provision that prohibits NorthView from soliciting other business combination proposals, which restricts NorthView’s ability, so long as the Merger Agreement is in effect, to consider other potential business combinations. • Risks regarding the stockholder vote.The risk that NorthView’s stockholders may fail to provide the votes necessary to effect the Merger. • Closing conditions.The fact that completion of the Merger is conditioned on the satisfaction of certain closing conditions that are not within NorthView’s control, including approval by NorthView’s stockholders and approval by Nasdaq of the initial listing application in connection with the Merger